AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

806.248

-3.677-0.45%

Number of Gainers:9

Number of Losers:14

Number of Flat:22

PE:- -

High:816.991

Open:809.925

Low:806.079

Close:809.925

Loading ...

Mayne Pharma Group Ltd - Seeks Over US$11.5 Mln in Damages From Txmd

THOMSON REUTERS

Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

These are the 10 most shorted ASX shares

Could these Australian fund managers be the next Warren Buffett?

What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?

Immuron Ltd - on Track to Exceed a$7 Mln in Sales This Year

THOMSON REUTERS

Immuron Letter to Shareholders: Projects Update

THOMSON REUTERS

Imugene Appoints Chief Medical Officer; Shares Hit All-Time Low

MT Newswires Live

Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment

MT Newswires Live

BRIEF-Patrys Seeks Trading Halt

Patrys Ltd - Seeks Trading Halt Pending Announcement on Operations Update

THOMSON REUTERS

Here are the top 10 ASX 200 shares today

Immuron Ltd-Proposed Issue of Securities - Imc

THOMSON REUTERS

Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%

MT Newswires Live

BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma

Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma

THOMSON REUTERS

Optiscan software breakthrough will bring pathologists to the bedside

The Sydney Morning Herald

Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%

MT Newswires Live

3 super strong ASX 200 blue chip shares to buy now

BUZZ-Australia's Oncosil Medical hits record low on discounted capital raise

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":806.24774,"timestamp":1749189599976,"preClose":809.925,"halted":0,"volume":49882817,"delay":0,"changeRate":-0.00454,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-3.677246,"latestTime":"06-06 16:00:00 AEST","open":809.925,"high":816.99097,"low":806.07916,"amount":127636809,"amplitude":0.013473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749168000000,1749189600000]],"turnoverRate":0.001585,"increases":8,"decrements":16,"flats":19,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":816.99097,"amplitude":0.013473,"preClose":809.925,"low":806.07916,"latestPrice":806.24774,"volume":49882817,"delay":0,"open":809.925,"prevYearClose":936.801,"prevWeekClose":825.374,"prevMonthClose":825.374,"prevQuarterClose":815.605,"fiveDayClose":825.374,"twentyDayClose":797.289,"sixtyDayClose":829.898,"secType":"PLATE","market":"AU","turnoverRate":0.001585,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617,"timestamp":1749189599976,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":9,"down":14,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540375872","title":"Mayne Pharma Group Ltd - Seeks Over US$11.5 Mln in Damages From Txmd","url":"https://stock-news.laohu8.com/highlight/detail?id=2540375872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540375872?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:18","pubTimestamp":1748819916,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nFWN3S303M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2540587417","title":"Immutep Ltd. Unveils Corporate Presentation Highlighting Advances in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2540587417","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540587417?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:17","pubTimestamp":1748819855,"startTime":"0","endTime":"0","summary":"Immutep Ltd. has released a corporate presentation highlighting its leadership in LAG-3 immunotherapy. The company is focusing on four clinical-stage assets and a preclinical program aimed at combating cancer and autoimmune diseases. The presentation details their first-in-class lead clinical candidates, including Efti, a novel MHC II agonist showing strong efficacy and a favorable safety profile in multiple cancers. Additionally, Immutep is conducting a Phase III trial in collaboration with MSD, evaluating Efti in combination with KEYTRUDA and chemotherapy for first-line treatment of non-small cell lung cancer. Immutep maintains full commercial rights to Efti. The company has multiple collaborations with large pharma and leading institutions. Immutep reports a strong intellectual property portfolio and a solid financial position with cash and cash equivalents of approximately A$146.25 million as of March 2025. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL5svFFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2540734758","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2540734758","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540734758?lang=en_us&edition=fundamental","pubTime":"2025-06-02 07:00","pubTimestamp":1748818821,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/02/these-are-the-10-most-shorted-asx-shares-2-june-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7504","PLS.AU","BK7145","BK7508","BK7095","IEL.AU","BOE.AU","BK7507","PNV.AU","BK7083","MIN.AU","PDN.AU","BK7509","BK7132","KAR.AU","BK7142","BK7126","LIC.AU","DYL.AU","LTR.AU"],"gpt_icon":0},{"id":"2540782312","title":"Could these Australian fund managers be the next Warren Buffett?","url":"https://stock-news.laohu8.com/highlight/detail?id=2540782312","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540782312?lang=en_us&edition=fundamental","pubTime":"2025-06-01 02:30","pubTimestamp":1748716200,"startTime":"0","endTime":"0","summary":"When Warren Buffett announced his retirement in May, investors immediately considered who would fill his shoes. In terms of his role as CEO of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), that ques","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/06/01/could-these-australian-fund-managers-be-the-next-warren-buffett/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00B3S45H60.SGD","NOW","NVD2.UK","NVDS","LU0289961442.SGD","LU0787776722.HKD","ALL.AU","RMD.AU","LU1674673428.USD","IE00BD6J9T35.USD","IE0004086264.USD","LU1923622614.USD","CSL.AU","3NVD.UK","XAO.AU","NVD3.UK","BRK.A","WTC.AU","DDOG","XJO.AU","LU0203201768.USD","LU1435385759.SGD","NVDY","LU1064131342.USD","BXB.AU","LU2249611893.SGD","GTK.AU","NVIW.SI","NVDS.UK","2NVD.UK","LU0094547139.USD","BK7508","BRK.B","NVDD","TNE.AU","LU0215105999.USD","NVDU","XKO.AU","BK4023","LU1868837300.USD","LU1429558221.USD","CAGR","CDA.AU","LU1935042991.SGD","SNVD.UK"],"gpt_icon":1},{"id":"2539222151","title":"What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222151","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222151?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:33","pubTimestamp":1748608426,"startTime":"0","endTime":"0","summary":"The GENIUS Act represents a groundbreaking federal regulatory framework for U.S. stablecoins, defining legal issuance standards, oversight responsibilities, consumer protections, and reserve requirements.  While its primary objective is to advance U.S. financial interests, it will significantly sha","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20231102/7520a74fa55c9128cdf6f43aa37d34fd.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20231102/7520a74fa55c9128cdf6f43aa37d34fd.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/cryptocurrencies/btc/250742655-genius-act-bitcoin-spot-etf-tradingkey-block-tao","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC","US30Y.BOND","US3Y.BOND","US5Y.BOND","BK1611","BTC.USD.HKCC","09008","US2Y.BOND","US7Y.BOND","BK4020","APT.USD.CC","83042","BK7508","03439","03042","09042","BK7067","BTC.USD.CC","OCC.AU","US10Y.BOND","09439","US6M.BOND","BK4594","TON.USD.CC","APT.USD.HKCC","FDN","BK4588","BK4601","BK4585","US12M.BOND","03008","TON.USD.HKCC"],"gpt_icon":1},{"id":"2539995223","title":"Immuron Ltd - on Track to Exceed a$7 Mln in Sales This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2539995223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539995223?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:00","pubTimestamp":1748599200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUADPKPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2539228020","title":"Immuron Letter to Shareholders: Projects Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2539228020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539228020?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:00","pubTimestamp":1748599200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUADPKPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2539221953","title":"Imugene Appoints Chief Medical Officer; Shares Hit All-Time Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2539221953","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539221953?lang=en_us&edition=fundamental","pubTime":"2025-05-30 11:09","pubTimestamp":1748574570,"startTime":"0","endTime":"0","summary":"Imugene (ASX:IMU) appointed John Byon as chief medical officer (CMO), effective immediately, according to a Friday filing with the Australian bourse.Byon succeeds outgoing CMO Paul Woodard, the filing said.Shares of the company fell 6% and earlier hit an all-time low.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMO.AU","BK7508","XAO.AU","BK7067","XJO.AU","IMU.AU","BK7095","XKO.AU"],"gpt_icon":0},{"id":"2539905282","title":"Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539905282","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539905282?lang=en_us&edition=fundamental","pubTime":"2025-05-30 09:00","pubTimestamp":1748566849,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2539294776","title":"BRIEF-Patrys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2539294776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539294776?lang=en_us&edition=fundamental","pubTime":"2025-05-30 07:51","pubTimestamp":1748562684,"startTime":"0","endTime":"0","summary":"BRIEF-Patrys Seeks Trading HaltMay 30 (Reuters) - Patrys Ltd PAB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON OPERATIONS UPDATEFurther company coverage: PAB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S12XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PAB.AU","BK7067"],"gpt_icon":0},{"id":"2539294741","title":"Patrys Ltd - Seeks Trading Halt Pending Announcement on Operations Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2539294741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539294741?lang=en_us&edition=fundamental","pubTime":"2025-05-30 07:50","pubTimestamp":1748562654,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nFWN3S12XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAB.AU"],"gpt_icon":0},{"id":"2539232514","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2539232514","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539232514?lang=en_us&edition=fundamental","pubTime":"2025-05-29 14:54","pubTimestamp":1748501651,"startTime":"0","endTime":"0","summary":"It was a mildly positive session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares this Thursday, building on the incremental gains we saw yesterday. By the time trading wrapped up, the ASX 200","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/29/here-are-the-top-10-asx-200-shares-today-29-may-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7504","BK7051","BK7096","ZIP.AU","BK7043","WDS.AU","BK7095","XYZ.AU","XJO.AU","NEU.AU","BK7508","BK7135","LTR.AU","AOV.AU","BK7142","BK7110","BK7503","JDO.AU","NIC.AU","CSC.AU","BK7158","BK7093","MP1.AU"],"gpt_icon":0},{"id":"2539235389","title":"Immuron Ltd-Proposed Issue of Securities - Imc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539235389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539235389?lang=en_us&edition=fundamental","pubTime":"2025-05-29 14:29","pubTimestamp":1748500162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUE2WW6BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2539282712","title":"Noxopharm Secures Ethics Approval for First-in-Human Trial of Inflammatory Disease Drug Candidate; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539282712","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539282712?lang=en_us&edition=fundamental","pubTime":"2025-05-29 11:47","pubTimestamp":1748490466,"startTime":"0","endTime":"0","summary":"Noxopharm  secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.Shares rose 6% in afternoon trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","NOX.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2538469544","title":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538469544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538469544?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:44","pubTimestamp":1748349870,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep’S Efti With Radiotherapy & KEYTRUDA Meets Primary Endpoint In Phase 2 For Soft Tissue SarcomaMay 27 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP’S EFTI WITH RADIOTHERAPY & KEYTRUDA (PEMBROLIZU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2538465765","title":"Immutep’s Efti With Radiotherapy & Keytruda® (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465765?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:00","pubTimestamp":1748347203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUALJCMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2538317724","title":"Optiscan software breakthrough will bring pathologists to the bedside","url":"https://stock-news.laohu8.com/highlight/detail?id=2538317724","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538317724?lang=en_us&edition=fundamental","pubTime":"2025-05-27 13:58","pubTimestamp":1748325480,"startTime":"0","endTime":"0","summary":"ASX-listed medical technology innovator Optiscan Imaging has just fired a major shot across the bow of the global diagnostics industry with the launch of its game-changing cloud-based telepathology pl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/optiscan-software-breakthrough-will-bring-pathologists-to-the-bedside-20250527-p5m2o1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["BK7508","MVP.AU","BK7096","MVP"],"gpt_icon":0},{"id":"2538487409","title":"Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538487409","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538487409?lang=en_us&edition=fundamental","pubTime":"2025-05-27 10:20","pubTimestamp":1748312448,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzym","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2538337486","title":"3 super strong ASX 200 blue chip shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2538337486","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538337486?lang=en_us&edition=fundamental","pubTime":"2025-05-27 07:29","pubTimestamp":1748302189,"startTime":"0","endTime":"0","summary":"Do you have room in your portfolio for some new ASX 200 blue chip shares?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/27/3-super-strong-asx-200-blue-chip-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","MQG.AU","BK7508","COH.AU","BK7501","BK7046","BK7007","BK7511","BK7067"],"gpt_icon":0},{"id":"2538123622","title":"BUZZ-Australia's Oncosil Medical hits record low on discounted capital raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2538123622","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538123622?lang=en_us&edition=fundamental","pubTime":"2025-05-26 11:15","pubTimestamp":1748229310,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Oncosil Medical hits record low on discounted capital raise** Oncosil Medical OSL.AX slides as much as 28.6% to a record low of A$0.003; last down 14.3%** Pharmaceutical co announces A$8.7 mln  capital raise at an issue price of A$0.003, a 25% discount to stock's last close** Says proceeds will fund and accelerate the ongoing commercialization of Oncosil medical device used to treat pancreatic cancer** Nearly 50 mln shares traded vs 30-day avg of 3 mln** Stock falls 41.7% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nL3N3RY06U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}]}}